Nagareddy Prabhakara Reddy, Soliman Hesham, Lin Guorong, Rajput Padmesh S, Kumar Ujendra, McNeill John H, MacLeod Kathleen M
Faculty of Pharmaceutical Sciences, The University of British Columbia, British Columbia, Canada.
Diabetes. 2009 Oct;58(10):2355-64. doi: 10.2337/db09-0432. Epub 2009 Jul 8.
Impaired cardiovascular function in diabetes is partially attributed to pathological overexpression of inducible nitric oxide synthase (iNOS) in cardiovascular tissues. We examined whether the hyperglycemia-induced increased expression of iNOS is protein kinase C-beta(2) (PKCbeta(2)) dependent and whether selective inhibition of PKCbeta reduces iNOS expression and corrects abnormal hemodynamic function in streptozotocin (STZ)-induced diabetic rats.
Cardiomyocytes and aortic vascular smooth muscle cells (VSMC) from nondiabetic rats were cultured in low (5.5 mmol/l) or high (25 mmol/l) glucose or mannitol (19.5 mmol/l mannitol + 5.5 mmol/l glucose) conditions in the presence of a selective PKCbeta inhibitor, LY333531 (20 nmol/l). Further, the in vivo effects of PKCbeta inhibition on iNOS-mediated cardiovascular abnormalities were tested in STZ-induced diabetic rats.
Exposure of cardiomyocytes to high glucose activated PKCbeta(2) and increased iNOS expression that was prevented by LY333531. Similarly, treatment of VSMC with LY333531 prevented high glucose-induced activation of nuclear factor kappaB, extracellular signal-related kinase, and iNOS overexpression. Suppression of PKCbeta(2) expression by small interference RNA decreased high-glucose-induced nuclear factor kappaB and extracellular signal-related kinase activation and iNOS expression in VSMC. Administration of LY333531 (1 mg/kg/day) decreased iNOS expression and formation of peroxynitrite in the heart and superior mesenteric arteries and corrected the cardiovascular abnormalities in STZ-induced diabetic rats, an action that was also observed with a selective iNOS inhibitor, L-NIL.
Collectively, these results suggest that inhibition of PKCbeta(2) may be a useful approach for correcting abnormal hemodynamics in diabetes by preventing iNOS mediated nitrosative stress.
糖尿病患者心血管功能受损部分归因于心血管组织中诱导型一氧化氮合酶(iNOS)的病理性过度表达。我们研究了高血糖诱导的iNOS表达增加是否依赖蛋白激酶C-β2(PKCβ2),以及选择性抑制PKCβ是否能降低iNOS表达并纠正链脲佐菌素(STZ)诱导的糖尿病大鼠的异常血流动力学功能。
将非糖尿病大鼠的心肌细胞和主动脉血管平滑肌细胞(VSMC)在低(5.5 mmol/l)或高(25 mmol/l)葡萄糖或甘露醇(19.5 mmol/l甘露醇 + 5.5 mmol/l葡萄糖)条件下,于选择性PKCβ抑制剂LY333531(20 nmol/l)存在的情况下进行培养。此外,在STZ诱导的糖尿病大鼠中测试了PKCβ抑制对iNOS介导的心血管异常的体内作用。
心肌细胞暴露于高葡萄糖会激活PKCβ2并增加iNOS表达,而LY333531可阻止这种情况。同样,用LY333531处理VSMC可防止高葡萄糖诱导的核因子κB、细胞外信号相关激酶的激活以及iNOS的过度表达。小干扰RNA抑制PKCβ2表达可降低高葡萄糖诱导的VSMC中核因子κB和细胞外信号相关激酶的激活以及iNOS表达。给予LY333531(1 mg/kg/天)可降低心脏和肠系膜上动脉中iNOS的表达以及过氧亚硝酸盐的形成,并纠正STZ诱导的糖尿病大鼠的心血管异常,选择性iNOS抑制剂L-NIL也观察到了这种作用。
总体而言,这些结果表明抑制PKCβ2可能是通过预防iNOS介导的亚硝化应激来纠正糖尿病患者异常血流动力学的一种有用方法。